Cargando…

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children

BACKGROUND: The antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV. Nevirapine is a known inhibitor of cytochrome P450 3A4, which metabolizes artemether and lumefantrine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Liusheng, Carey, Vincent, Lindsey, Jane C., Marzan, Florence, Gingrich, David, Graham, Bobbie, Barlow-Mosha, Linda, Ssemambo, Phionah K., Kamthunzi, Portia, Nachman, Sharon, Parikh, Sunil, Aweeka, Francesca T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655345/ https://www.ncbi.nlm.nih.gov/pubmed/29065172 http://dx.doi.org/10.1371/journal.pone.0186589

Ejemplares similares

Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children
por: Kajubi, Richard, et al.
Publicado: (2016)

The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
por: Whalen, Meghan E, et al.
Publicado: (2022)

Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients
por: Huang, Liusheng, et al.
Publicado: (2018)

Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria
por: Nyunt, Myaing M., et al.
Publicado: (2016)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
por: Tchaparian, Eskouhie, et al.
Publicado: (2016)

Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort
por: Mosha, Dominic, et al.
Publicado: (2014)

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes
por: Abdullahi, Sa’ad T., et al.
Publicado: (2020)

Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
por: Belew, Sileshi, et al.
Publicado: (2020)

Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration
por: Akpa, Paul Achile, et al.
Publicado: (2020)

The clinical efficacy of artemether/lumefantrine (Coartem(®))
por: Makanga, Michael, et al.
Publicado: (2009)

A Modified Method for Determination of Lumefantrine in Human Plasma by HPLC-UV and Combination of Protein Precipitation and Solid-Phase Extraction: Application to a Pharmacokinetic Study
por: Huang, Liusheng, et al.
Publicado: (2010)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
por: Ali, Shabana, et al.
Publicado: (2010)

Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
por: Nyangulu, Wongani, et al.
Publicado: (2023)

Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma
por: Sok, Vong, et al.
Publicado: (2021)

Quality Assessment of Artemether-Lumefantrine Samples and Artemether Injections Sold in the Cape Coast Metropolis
por: Prah, James, et al.
Publicado: (2016)

Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
por: Ehrhardt, Stephan, et al.
Publicado: (2009)

Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019
por: Dimbu, Pedro Rafael, et al.
Publicado: (2021)

Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine
por: Shekalaghe, Seif, et al.
Publicado: (2020)

Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination
por: Gerardin, Jaline, et al.
Publicado: (2015)

The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
por: Bassat, Quique
Publicado: (2011)

Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India
por: Valecha, Neena, et al.
Publicado: (2009)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Artemether/Lumefantrine for the Treatment of P. malariae in a Patient on Hemodialysis
por: Patrocínio-Jesus, Rita, et al.
Publicado: (2019)

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali
por: Diarra, Modibo, et al.
Publicado: (2021)

Adverse reaction to Coartem (artemether/lumefantrine) resulting in oculogyric crisis
por: Amponsah, Emmanuel Kofi, et al.
Publicado: (2021)

Pharmacopeial quality of artemether–lumefantrine anti-malarial agents in Uganda
por: Ocan, Moses, et al.
Publicado: (2023)

Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria
por: Chotsiri, Palang, et al.
Publicado: (2019)

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
por: Peto, Thomas J, et al.
Publicado: (2022)

Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda
por: Checchi, Francesco, et al.
Publicado: (2006)

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
por: Sipilanyambe, Naawa, et al.
Publicado: (2008)

Malaria case-management under artemether-lumefantrine treatment policy in Uganda
por: Zurovac, Dejan, et al.
Publicado: (2008)

Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
por: Gürkov, Robert, et al.
Publicado: (2008)

Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children
por: Abdulla, Salim, et al.
Publicado: (2009)

Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
por: Ogutu, Bernhards, et al.
Publicado: (2010)

Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania
por: Mugoyela, V, et al.
Publicado: (2011)

Formulation, process development and evaluation of artemether and lumefantrine soft gelatin capsule
por: Patel, A., et al.
Publicado: (2012)

Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda
por: Rulisa, Stephen, et al.
Publicado: (2012)

A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission
por: Makanga, Michael
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u3urdrinrivs96nt28ma9drabm